Regulus Therapeutics (RGLS) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGLS shares.
View RGLS analyst ratings or view top-rated stocks.

3 brokers have issued 1-year target prices for Regulus Therapeutics' shares. Their RGLS share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 576.7% from the stock's current price.
View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts.

Regulus Therapeutics' stock was trading at $1.37 at the beginning of 2023. Since then, RGLS stock has decreased by 2.9% and is now trading at $1.33.
View the best growth stocks for 2023 here.

Regulus Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 253,700 shares, an increase of 26.0% from the April 30th total of 201,300 shares. Based on an average daily trading volume, of 67,000 shares, the short-interest ratio is presently 3.8 days. Approximately 1.6% of the shares of the stock are short sold.
View Regulus Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RGLS earnings forecast.

Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings results on Thursday, March, 23rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09.

Regulus Therapeutics shares reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Regulus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends.

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGLS stock can currently be purchased for approximately $1.33.

Regulus Therapeutics (NASDAQ:RGLS) has a market capitalization of $25.91 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-28,320,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.regulusrx.com. The biopharmaceutical company can be reached via phone at (858) 202-6300 or via email at ccalsada@regulusrx.com.